Amgen 2007 Annual Report Download - page 118

Exhibit No. Description
10.55 G-CSF United States License Agreement, dated June 1, 1987 (effective July 1, 1986), Amendment
No. 1, dated October 20, 1988, and Amendment No. 2, dated October 17, 1991 (effective
November 13, 1990), between Kirin-Amgen, Inc. and Amgen Inc. (Filed as exhibits to Form 10-K
for the year ended December 31, 2000 on March 7, 2001 and incorporated herein by reference.)
10.56 G-CSF European License Agreement, dated December 30, 1986, between Kirin-Amgen and
Amgen, Amendment No. 1 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement,
dated June 1, 1987, Amendment No. 2 to Kirin-Amgen, Inc. / Amgen G-CSF European License
Agreement, dated March 15, 1998, Amendment No. 3 to Kirin-Amgen, Inc. / Amgen G-CSF
European License Agreement, dated October 20, 1988, and Amendment No. 4 to Kirin-Amgen,
Inc. / Amgen G-CSF European License Agreement, dated December 29, 1989, between Kirin-
Amgen, Inc. and Amgen Inc. (Filed as exhibits to Form 10-K for the year ended December 31,
2000 on March 7, 2001 and incorporated herein by reference.)
10.57 Enbrel®Supply Agreement among Immunex Corporation, American Home Products Corporation
and Boehringer Ingelheim Pharma KG, dated as of November 5, 1998 (with certain confidential
information deleted therefrom). (Filed as an exhibit to the Immunex Corporation Annual Report
on Form 10-K for the year ended December 31, 1998 on March 23, 1998 and incorporated herein
by reference.)
10.58 Amendment No. 1 to the Enbrel®Supply Agreement, dated June 27, 2000, among Immunex
Corporation, American Home Products Corporation and Boehringer Ingelheim Pharma KG, (with
certain confidential information deleted therefrom). (Filed as an exhibit to the Immunex
Corporation Form 10-Q for the quarter ended June 30, 2000 on August 11, 2000 and incorporated
herein by reference.)
10.59 Amendment No. 2 to the Enbrel®Supply Agreement, dated June 3, 2002, among Immunex
Corporation, Wyeth (formerly known as American Home Products Corporation) and Boehringer
Ingelheim Pharma KG (with certain confidential information deleted therefrom). (Filed as an
exhibit to Form 10-Q for the quarter ended June 30, 2002 on August 13, 2002 and incorporated
herein by reference.)
10.60 Amendment No. 3 to the Enbrel®Supply Agreement, dated December 18, 2002, among Immunex
Corporation, Wyeth (formerly, “American Home Products Corporation”) and Boehringer
Ingelheim Pharma KG (with certain confidential information deleted therefrom). (Filed as an
exhibit to Form 10-K for the year ended December 31, 2002 on March 10, 2003 and incorporated
herein by reference.)
10.61 Amendment No. 4 to the Enbrel®Supply Agreement, dated May 21, 2004, among Immunex
Corporation, Wyeth (formerly, “American Home Products Corporation”) and Boehringer
Ingelheim Pharma KG. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2005 on
August 8, 2005 and incorporated herein by reference.)
10.62 Amendment No. 5 to the Enbrel®Supply Agreement, dated August 30, 2005, among Immunex
Corporation, Wyeth (formerly, “American Home Products Corporation”) and Boehringer
Ingelheim Pharma KG. (Filed as an exhibit to Form 10-Q for the quarter ended September 30,
2005 on November 9, 2005 and incorporated herein by reference.)
10.63* Amendment No. 6 to the Enbrel®Supply Agreement, dated November 27, 2007, among Immunex
Corporation, Wyeth (formerly, “American Home Products Corporation”) and Boehringer
Ingelheim Pharma KG (with certain confidential information deleted therefrom).
10.64 Agreement Regarding Governance and Commercial Matters, dated December 16, 2001, by and
among American Home Products Corporation, American Cyanamid Company and Amgen Inc.
(with certain confidential information deleted therefrom). (Filed as an exhibit to Amendment No.
1 to Form S-4 Registration Statement on March 22, 2002 and incorporated herein by reference.)
106